Targeting TG remains a promising approach for reducing cardiovascular (CV) risk, but growing evidence suggests that TG-lowering agents need to reduce apoB-containing proteins as well as TG to have beneficial effects on residual risk, Dr Giovanna Liuzzo (IRCCS Foundation Agostino Gemelli University Hospital, Rome, Italy) told delegates during her presentation.
Educational partners and supporters
Financial support was provided as a GMG Knowledge Gap Grant from Pfizer Inc.
Financial support was provided as a GMG Knowledge Gap Grant from Pfizer Inc.
Financial support was provided as a GMG Knowledge Gap Grant from Pfizer Inc.
